NCT05732701Recruiting
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2788 (estimated)
- First submitted
- 8 Feb 2023
- Start date
- 27 Jun 2023
- Primary completion date
- Dec 2029
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Coronary artery disease
- NCT number
- NCT05732701
What you commit to
- Study type: Interventional
- Planned participants: 2788
- From 27 Jun 2023 to the primary completion date, Dec 2029
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment for stent thrombosis at qualifying PCI or within 1 year prior to qualifying PCI
- Planned surgery within the next 3 months
- Participation in a drug trial
Other illness
- Peri-procedural complication which affects DAPT regimen based on the operator's opinion (e.g. untreated flow-limiting angiographic complication, intraprocedural stent thrombosis, persistent vessel occlusion/no-reflow at the end of the procedure, major side-branch occlusion, puncture-site related or other relevant bleeding)
- Active bleeding requiring medical attention at qualifying PCI
- Contraindication or known allergy against aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel)
Other
- Planned staged PCI (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop an indication for percutaneous valve intervention can undergo treatment 30 days after full coronary revascularization)
- Indication for oral anticoagulation
- The presence of hemodynamic instability (persistent systolic blood pressure below 90mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices)
- Life expectancy less than 1 year
- Women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile)
Who the study is looking for
- PCI with drug eluting stent (DES) implantation
- Age ≥18 years
- Ability to sign informed consent before any study-specific procedure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Cardiology, Bern University Hospital Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| Kardiologie Spitalzentrum Biel Coordinator of this site? Confirm its status | Biel/Bienne | Switzerland | Recruiting |
| UOC Cardiologia San Giovanni Addolorata Hospital Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
| University Clinical Center of the Republic of Srpska Coordinator of this site? Confirm its status | Banja Luka | Bosnia and Herzegovina | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.